recent
outbreak
requir
urgent
treatment
numer
patient
origin
wuhan
china
spread
contin
caus
signific
harm
public
fig
repres
transmiss
electron
microscop
imag
along
structur
coronaviru
suitabl
vaccin
antivir
drug
exist
time
write
march
coronaviru
case
alreadi
last
h
day
death
last
h
day
vs
recov
last
h
improv
china
howev
condit
deterior
western
europ
especi
itali
cure
known
time
addit
administ
oxygen
current
treatment
recommend
world
health
organ
seriou
critic
case
includ
remdesivir
kaletra
kaletra
plu
interferon
conquer
coronaviru
press
goal
research
pari
remdesivir
antivir
nucleotid
develop
treatment
ebola
viru
marburg
viru
infect
kaletra
combin
lopinavir
ritonavir
lpvr
also
use
antivir
nucleotid
analog
develop
treatment
hivaid
third
option
combin
kaletra
interferon
interferon
signal
protein
cytokin
infect
cell
produc
releas
respons
virus
interferon
activ
cell
immun
system
stronger
immun
system
respons
achiev
interferon
alpha
specif
recommend
viral
infect
cancer
efficaci
process
controversi
therefor
altern
approach
urgent
need
china
death
rate
peak
week
ago
declin
good
result
obtain
use
interferon
alpha
ifnrec
without
combin
kaletra
use
intraven
iv
vitamin
c
vitc
shown
promis
area
china
iv
vitc
ascorb
acid
protocol
mention
clinicaltrialsgov
patholog
shanghai
util
iv
vitc
treatment
mani
physician
china
identifi
promis
result
use
iv
vitc
thu
need
urgent
review
use
iv
vitc
preand
postinfect
differ
stage
infect
iv
vitc
help
develop
stronger
immun
system
respons
reduc
cytokin
storm
increas
antivir
activ
unknown
mechan
perhap
reduct
cytokin
storm
late
stage
infect
signific
applic
iv
vitc
pneumonia
complex
medic
disord
high
morbid
mortal
rate
caus
sever
lung
injuri
result
acut
respiratori
distress
syndrom
ard
lifethreaten
lung
disord
process
prevent
necessari
oxygen
enter
lung
ultim
caus
death
coronavirus
increas
oxid
stress
promot
cellular
malfunct
ultim
result
organ
failur
believ
pulmonari
failur
ard
princip
caus
action
human
help
increas
oxid
stress
consider
gener
free
radic
cytokin
process
final
lead
seriou
cellular
injuri
organ
failur
death
administr
antioxid
agent
along
proven
convent
support
therapi
believ
import
role
control
medic
situat
appropri
vaccin
antivir
drug
epidem
avail
iv
vitamin
c
antioxid
extrem
good
agent
ard
appli
clinic
importantli
high
dose
iv
vitc
safe
effect
paper
review
use
highdos
vitc
effici
method
treatment
patient
cancer
infect
antivir
properti
vitc
help
reduc
symptom
mortal
children
adult
antivir
activ
ascorb
acid
known
publish
almost
year
ago
scientist
involv
work
poliomyel
moreov
use
ascorb
acid
medicin
crucial
agent
variou
diseas
also
well
establish
applic
vitc
found
poliomyel
mani
use
vitc
includ
hepat
herp
chickenpox
measl
infecti
mononucleosi
trichinosi
urethr
antabus
arthriti
cancer
vitc
also
help
treatment
elev
cholesterol
arteriosclerosi
corneal
ulcer
glaucoma
burn
heatstrok
sunburn
slip
disc
toxin
heavi
metal
poison
appropri
clinic
effect
vaccin
specif
antivir
may
serv
effect
avail
consid
current
situat
use
vitc
antivir
agent
also
consid
notabl
vitc
use
alon
combin
avail
medicin
exert
posit
synergist
effect
review
princip
mechan
action
iv
vitc
help
make
immun
system
stronger
reduc
cytokin
storm
inhibit
oxid
process
first
criteria
literatur
knowledg
cancer
treatment
review
first
antivir
properti
review
focus
reduct
oxid
pathway
typic
ard
review
laboratori
anim
human
studi
current
clinic
trial
provid
regard
cancer
treatment
vitc
crucial
nutrient
redox
properti
cofactor
numer
enzym
play
import
role
synthesi
collagen
defici
vitc
may
result
scurvi
scurvi
caus
collagen
structur
narrow
thin
found
normal
healthi
situat
maintain
administr
vitc
centuri
studi
hypothes
cancer
origin
due
alter
structur
connect
tissu
caus
vitc
defici
review
suggest
highdos
ascorb
acid
enhanc
host
resist
studi
also
identifi
use
ascorb
acid
cancer
therapi
gener
vitc
synthes
isomer
sugar
dglucos
dgalactos
numer
plant
anim
interestingli
human
lack
enzym
lgulonolacton
oxidas
requir
ascorb
acid
synthesi
basi
human
need
vitc
food
supplement
vitc
essenti
nutrient
redox
properti
normal
physiolog
situat
cancer
patient
treat
success
highdos
oral
andor
iv
vitc
howev
two
earli
random
placebocontrol
studi
highdos
oral
vitc
gd
indic
signific
effect
cancer
studi
indic
margin
medic
benefit
ascorbateand
placebotr
group
laboratori
experi
report
highdos
vitc
decreas
cell
prolifer
prostat
pancreat
colon
mesothelioma
neuroblastoma
cancer
cell
line
studi
vitc
combin
medicin
anim
model
demonstr
inconclus
result
importantli
iv
vitc
welltoler
clinic
trial
iv
administr
vitc
mg
found
effect
oral
administr
sinc
higher
blood
concentr
ascorb
found
iv
rout
studi
vitc
ascorb
versu
ascorb
formul
along
standard
cancer
therapi
perform
clinic
trial
two
studi
highdos
vitc
confirm
better
qualiti
life
fewer
cancerrel
toxic
result
preclin
clinic
trial
highdos
vitc
without
standard
cancer
therapi
noteworthi
howev
may
challeng
investig
shortcom
use
highdos
vitc
iv
oral
manag
cancer
start
five
decad
ago
applic
vitc
therapi
treatment
variou
cancer
promot
exampl
two
clinic
trial
vitc
conduct
mani
year
ago
pharmacokinet
experi
identifi
consider
differ
maximum
achiev
blood
concentr
vitc
found
natur
rout
deliveri
relev
exampl
vitc
taken
oral
plasma
concentr
control
peak
achiev
concentr
less
howev
control
bypass
iv
administr
vitamin
result
high
level
vitc
plasma
concentr
mm
addit
research
suggest
pharmacolog
concentr
ascorb
achiev
iv
administr
may
result
cell
death
numer
cancer
cell
line
health
care
practition
particip
complementari
altern
medicin
confer
debat
benefitsrisk
highdos
iv
vitc
patient
total
particip
chosen
taken
vitc
specif
iv
vitc
recommend
fight
infect
cancer
fatigu
earli
case
studi
conduct
cancer
patient
taken
high
dose
ascorb
acid
convent
therapi
appli
patient
success
basi
patient
recommend
take
ascorb
acid
differ
dose
schedul
use
exampl
patient
given
iv
ascorb
acid
gday
success
day
given
higher
dose
amount
chosen
give
oral
ascorb
acid
gday
combin
wide
varieti
respons
found
dome
minim
respons
tumor
regress
tumor
hemorrhag
despit
import
observ
lack
control
studi
prevent
make
conclus
health
benefit
ascorb
acid
treatment
limit
studi
publish
appar
one
patient
experienc
tumor
regress
patient
reticulum
cell
sarcoma
exhibit
improv
due
treatment
ascorb
acid
reduct
daili
dose
ascorb
acid
help
sinc
symptom
diseas
appear
notabl
remiss
success
achiev
patient
given
higher
initi
dose
ascorb
acid
larger
studi
termin
cancer
patient
treat
ascorb
conduct
investig
termin
cancer
patient
given
ascorb
accept
scientif
way
gday
day
iv
repeat
oral
health
condit
patient
evalu
concern
match
control
patient
clinic
interestingli
averag
surviv
time
ascorbatetr
patient
consider
much
higher
day
match
control
group
two
random
investig
use
placebocontrol
trial
perform
studi
cancer
patient
taken
either
g
oral
vitc
placebo
daili
sign
cancer
go
away
end
investig
signific
differ
clinic
result
found
two
ascorbateand
placebotr
group
studi
disclos
three
case
report
cancer
patient
receiv
iv
vitc
main
medicin
vitc
uptak
patient
also
given
materi
includ
vitamin
miner
botan
claim
case
analyz
follow
nation
cancer
institut
nci
best
case
seri
procedur
histopatholog
test
found
weak
prognos
patient
surviv
period
patient
went
treat
iv
vitc
vitc
given
g
g
twice
week
sever
month
patient
two
studi
demonstr
iv
vitc
treatment
help
improv
qualiti
life
decreas
side
effect
associ
cancer
systemat
studi
identifi
dose
vitc
volunt
cancer
patient
gkg
toxic
risk
seen
exampl
dehydrogenas
defici
renal
diseas
urolithiasi
studi
identifi
plasma
concentr
vitc
much
higher
iv
administr
oral
administr
concentr
maintain
approxim
h
phase
studi
investig
safeti
effici
dual
drug
therapi
combin
iv
ascorb
gemcitabin
erlotinib
stage
iv
pancreat
cancer
patient
fourteen
subject
evalu
studi
patient
receiv
iv
gemcitabin
mg
min
week
week
oral
erlotinib
mg
daili
week
iv
ascorb
ginfus
ginfus
ginfus
time
per
week
week
advers
effect
observ
ascorb
acid
treatment
five
subject
receiv
fewer
propos
ascorb
infus
three
patient
diseas
continu
imag
test
perform
nine
patient
assess
tumor
size
show
health
situat
stabl
phase
clinic
investig
studi
effect
combin
ascorb
gemcitabin
treatment
stage
iv
pancreat
cancer
cycl
patient
given
gemcitabin
weekli
week
ascorb
week
specif
dose
studi
found
progressionfre
overal
surviv
period
combin
drug
treatment
accept
well
phase
iiia
clinic
trial
measur
toxic
two
system
first
one
combin
iv
ascorb
carboplatin
second
one
ascorb
paclitaxel
stage
iiiiv
ovarian
cancer
patient
chosen
receiv
either
chemotherapi
alon
chemotherapi
iv
vitc
chemotherapi
given
month
iv
vitc
continu
month
interestingli
iv
vitc
reduc
chemotherapyrel
toxic
phase
iii
clinic
trial
highdos
iv
vitc
numer
chemotherapeut
agent
conduct
studi
perform
evalu
multipl
factor
import
target
evalu
associ
advers
effect
determin
pharmacokinet
activ
vitc
understand
clinic
potenti
evalu
chang
mood
behavior
assess
lifestyl
highdos
iv
vitc
analyz
patient
procedur
perform
toler
well
safe
temporari
side
effect
seen
increas
urinari
flow
thirst
nausea
vomit
chill
import
note
administr
chemotherapeut
agent
alter
plasma
concentr
vitc
patient
benefit
treatment
experi
temporari
stabl
diseas
demonstr
activ
addit
energi
howev
sinc
group
small
gener
conclus
studi
drawn
recent
phase
studi
evalu
evalu
safeti
bioavail
effici
highdos
iv
vitc
combin
chemotherapi
regimen
folfiri
combin
wellknown
agent
oxaliplatin
leucovorin
leucovorin
irinotecan
hydrochlorid
studi
conduct
patient
metastat
colorect
gastric
cancer
princip
aim
evalu
maximumtoler
dose
anoth
goal
determin
phase
ii
dose
ascorb
acid
coadministr
folfiri
initi
patient
given
ident
chemotherapi
treatment
day
vitc
infus
later
concentr
ascorb
acid
alter
doseescal
investig
studi
demonstr
doselimit
toxic
therefor
maximumtoler
dose
identifi
investig
howev
dose
gkg
ascorb
acid
recommend
phase
ii
studi
advers
side
effect
observ
treatment
accept
patient
base
success
random
phase
iii
investig
progress
goal
studi
determin
clinic
power
ascorb
acid
metastat
colorect
cancer
combin
without
bevacizumab
sever
studi
perform
small
dose
iv
ascorb
acid
boretti
bk
banik
pharmanutrit
treatment
mg
arsen
trioxid
regimen
mix
result
obtain
clinic
investig
ascorb
combin
arsen
trioxid
report
patient
nonsmal
cell
lung
carcinoma
nsclc
glioblastoma
multiform
gbm
treat
two
clinic
trial
patient
trial
undergon
convent
therapi
along
iv
vitc
iv
vitc
administ
radiat
therapi
presenc
temozolomid
toxic
overal
surviv
rate
patient
favor
nsclc
clinic
trial
phase
ii
procedur
patient
advanc
cancer
patient
also
given
chemotherapi
iv
vitc
result
investig
also
favor
mani
trial
iv
vitc
combin
medicin
activ
investig
accordingli
trial
conduct
scientist
iowa
univers
phase
ii
studi
phase
ibii
trial
phase
ii
clinic
trial
focus
identifi
effici
highdos
ascorb
acid
combin
common
anticanc
molecul
studi
ascorb
also
progress
mani
cancer
cell
line
includ
studi
nonsmal
cell
lung
cancer
therapi
radiat
therapi
presenc
carboplatin
paclitaxel
metastat
pancreat
adenocarcinoma
presenc
gemcitabin
nabpaclitaxel
pancreat
adenocarcinoma
presenc
gemcitabin
radiat
therapi
glioblastoma
presenc
temozolomid
radiat
therapi
anoth
phase
ibii
trial
investig
safeti
clinic
perform
highdos
ascorb
radiat
therapi
soft
tissu
sarcoma
numer
studi
use
iv
ascorb
acid
fix
dose
mg
variou
amount
arsen
trioxid
anticanc
therapi
expect
prooxid
charact
iv
ascorb
acid
improv
effect
arsen
trioxid
sensit
process
malign
cell
arsen
cytotox
natur
combin
therapi
work
well
benefit
multipl
myeloma
observ
howev
role
vitc
determin
contrast
similar
combin
regimen
effect
result
side
effect
includ
progress
diseas
particular
cancer
moreov
anticanc
effect
metastat
colorect
cancer
metastat
melanoma
determin
sinc
trial
placebocontrol
role
ascorb
acid
result
unclear
intraven
iv
highdos
ascorb
acid
welltoler
clinic
trial
specul
ascorb
acid
may
acceler
renal
failur
patient
preexist
renal
disord
dehydrogenas
defici
patient
good
candid
high
dose
vitc
due
hemolysi
vitc
abl
improv
bioavail
iron
larg
dose
vitc
recommend
patient
hemochromatosi
vitc
high
dose
react
anticanc
compound
interact
detect
preclin
studi
phase
clinic
investig
examin
feasibl
use
highdos
iv
ascorb
gemcitabin
stage
iv
pancreat
cancer
patient
import
know
combin
formula
well
toler
patient
advers
effect
observ
vitro
vivo
anim
studi
indic
ascorb
alter
mechan
drug
exampl
ascorb
bortezomib
alter
action
medicin
proteasom
inhibit
agent
block
bortezomibmedi
cell
death
interact
observ
low
concentr
vitc
mgkgday
anim
cell
cultur
studi
blood
plasma
vitc
gday
also
demonstr
larg
decreas
bortezomib
growth
inhibitori
effect
multipl
myeloma
cell
plasma
healthi
volunt
analyz
bortezomib
growth
inhibit
multipl
myeloma
cell
observ
person
take
g
oral
vitc
per
day
amount
block
drug
inhibitori
properti
proteasom
hand
studi
util
mice
harbor
human
prostat
cancer
cell
xenograft
find
good
effect
oral
vitc
mgkgday
mgkgday
tumor
growth
inhibitori
action
medicin
studi
show
dehydroascorb
acid
oxid
form
vitc
alter
cytotox
properti
chemotherapi
drug
concentr
dehydroascorb
acid
found
low
dietari
supplement
food
despit
controversi
result
year
vitc
proven
anticanc
effect
given
intraven
high
concentr
report
anticanc
activ
vitc
depend
use
immunedefici
mice
studi
conduct
examin
direct
effect
ascorb
tumor
found
effect
vitamin
c
much
stronger
presenc
intact
immun
system
observ
suggest
combin
treatment
requir
evalu
patient
antivir
properti
vitc
recent
review
vitc
use
treatment
hypovitaminosi
c
malnourish
patient
combin
hydrocortison
ascorb
acid
thiamin
hat
therapi
work
well
treatment
patient
sepsi
septic
shock
ongo
complet
clinic
trial
vitc
administr
sepsi
effect
vitc
prevent
common
cold
health
disord
question
ascorb
acid
therapi
acut
inflammatori
disord
base
upon
numer
biolog
studi
follow
mani
decad
research
current
interest
vitc
focus
bacteri
sepsi
septic
shock
patient
scientif
clinic
studi
support
mechanist
data
use
vitc
diseas
addit
role
vitc
treatment
viral
diseas
also
possibl
biolog
concept
evid
use
vitc
viral
infect
describ
numer
studi
identifi
vitc
high
dosag
virucid
conclus
base
invitro
experi
presenc
copper
andor
iron
high
dose
vitc
show
virucid
activ
explain
format
hydrogen
peroxid
radic
initi
moreov
low
ph
valu
system
respons
invitro
antivir
effect
vitc
despit
studi
vivo
virucid
activ
vitc
confirm
well
establish
vitc
power
antioxid
exert
prooxid
effect
high
concentr
gener
reactiv
oxygen
speci
reduct
transit
metal
possibl
found
highdos
one
sodium
salt
ascorb
acid
mm
kill
candida
albican
invitro
ironcatalyz
fenton
reaction
iron
chelat
inhibit
effect
experi
demonstr
vitc
decreas
viral
load
ebsteinbarr
viru
ebv
observ
suggest
multipl
mechan
involv
vitccontrol
antivit
therapi
activ
antigen
load
reduc
pretreat
human
foreskin
fibroblast
endotheli
cell
ascorb
cytomegaloviru
cmv
infect
observ
fail
reproduc
ascorb
ad
infect
immunomodulatori
activ
vitc
respons
effect
gener
ascorb
acid
concentr
leucocyt
lymphocyt
macrophag
chemotaxi
improv
vitc
neutrophil
phagocyt
activ
oxid
death
also
enhanc
lymphocyt
prolifer
also
acceler
ratedetermin
last
step
ascorb
acid
biosynthesi
anim
oxidas
isomer
gulo
form
mutat
gene
enzym
prevent
anthropoid
primat
guinea
pig
synthes
molecul
effect
vitc
viral
infect
studi
via
gulo
knockout
mice
system
shown
nasal
inocul
influenza
viru
fatal
gulo
mice
comparison
wild
type
mice
antivir
cytokin
interferon
ifn
becam
lower
howev
viral
titer
lung
ascorb
acidinsuffici
gulo
mice
becam
abund
proinflammatori
cytokin
tumor
necrosi
factor
tnf
infiltr
inflammatori
cell
increas
lung
result
correct
gulo
mice
replet
ascorb
acid
viral
exposur
occur
probabl
impair
phosphoryl
process
signal
transduc
activ
transcript
stat
respons
decreas
gener
ifn
gulo
mice
found
gulo
mice
compar
wild
type
mice
impair
immun
respons
higher
lung
patholog
dysfunct
expos
influenza
viru
shown
restraintstress
mice
pneumonia
dosedepend
reduct
mortal
presenc
ascorb
histopatholog
lung
section
also
demonstr
reduc
problem
treat
mice
administr
vitc
help
recov
mitochondri
membran
potenti
gene
express
proinflammatori
cytokin
ascorb
acid
report
clinic
activ
numer
virus
includ
polioviru
venezuelan
equin
enceph
human
lymphotrop
viru
type
human
immunodefici
viru
hiv
rabi
viru
addit
demonstr
activ
influenza
herp
viru
known
infect
activ
phagocyt
gener
reactiv
oxygen
speci
ro
ro
key
role
deactiv
virus
ro
harm
host
cell
caus
viralinduc
host
injuri
respiratori
syncyti
viru
rsv
infect
upper
lower
respiratori
tract
infant
children
rsv
infect
airway
epitheli
cell
acceler
ro
product
inhibit
concentr
lung
antioxid
enzym
oxidantantioxid
amount
proport
cell
critic
rsv
pulmonari
toxic
lung
pulmonari
inflamm
injuri
consider
reduc
administr
antioxid
ascorb
acid
power
antioxid
therefor
scaveng
oxygen
free
radic
restor
cellular
antioxid
includ
tetrahydrobiopterin
hypothesi
vitc
may
becom
benefici
treatment
viral
infect
base
two
concept
patient
infecti
diseas
suffici
level
vitc
due
metabol
consumpt
vitc
immunomodul
properti
patient
viral
infect
possibl
increas
product
interferon
downregul
synthesi
proinflammatori
cytokin
despit
vitc
benefici
effect
viral
infect
solid
clinic
data
exist
topic
paul
suggest
vitc
use
treatment
common
cold
basi
random
control
trial
rct
target
role
vitc
prevent
treatment
cold
symptom
analysi
rct
vitc
fail
reduc
cold
diseas
consist
effect
vitc
observ
also
durat
cold
patient
sever
studi
howev
complic
interpret
data
ascorb
acid
may
clinic
effect
patient
infect
caus
herp
virus
herp
zoster
hzv
infect
take
place
due
reactiv
latent
varicellazost
viru
vzv
particularli
predomin
loss
cellinduc
immun
age
concentr
ascorb
acid
plasma
decreas
postherpet
neuralgia
patient
compar
healthi
person
rct
studi
conduct
patient
subject
iv
vitc
mgkg
day
placebo
found
patient
taken
iv
vitc
experienc
less
pain
nonblind
rct
role
ascorb
acid
acut
herpet
pain
postherpet
neuralgia
evalu
eightyseven
patient
given
g
iv
ascorb
acid
first
third
fifth
day
placebo
interestingli
differ
group
observ
treat
group
vitc
demonstr
lower
incid
postherpet
neuralgia
lower
pain
score
vitc
mostli
concentr
aqueou
humor
anterior
chamber
eye
retrospect
cohort
investig
indic
oral
vitc
reduc
risk
herp
simplex
kerat
combin
oral
antivir
drug
conclud
month
start
epidem
urgent
need
novel
research
applic
iv
vitc
target
manag
infecti
diseas
influenza
viru
caus
epidem
pandem
kill
thousand
peopl
everi
year
experiment
studi
demonstr
benefici
effect
ascorb
acid
influenza
patient
respiratori
disord
due
infect
influenza
treat
histon
acetyltransferas
hat
without
corticosteroid
remark
patient
show
rapid
improv
initi
hat
corticosteroid
hand
complex
role
treatment
infect
result
corticosteroid
may
standard
choic
patient
influenza
infect
effect
clinic
trial
necessari
investig
use
vitc
infect
due
influenza
rsv
herp
viral
ill
larg
dose
iv
ascorb
acid
one
treatment
choic
pneumonia
report
diseas
indic
sever
exampl
icu
admiss
mortal
rate
observ
among
case
believ
ard
main
mechan
action
follow
increas
oxid
stress
releas
free
radic
cytokin
consid
mechan
process
larg
dose
vitc
play
key
role
manag
studi
indic
patient
develop
ard
eleven
patient
pass
away
due
multipl
organ
failur
death
explain
due
increas
oxid
stress
cytokin
gener
lead
ard
like
influenza
coronavirus
pandem
virus
injur
lung
drastic
viral
infect
gener
storm
cytokin
react
endotheli
cell
lung
interact
caus
neutrophil
infiltr
enhanc
oxid
stress
damag
function
lung
barrier
ard
character
strong
hypoxemia
propag
multipl
reason
uncontrol
inflamm
oxid
injuri
damag
alveolarcapillari
barrier
main
reason
sever
increas
oxid
stress
caus
pulmonari
injuri
lung
injuri
ali
ard
ali
ard
key
factor
respons
substanti
high
morbid
mortal
increas
creactiv
protein
hscrp
indic
inflamm
oxid
stress
seen
among
patient
transcript
factor
nuclear
factor
major
regul
antioxid
respons
element
driven
cytoprotect
protein
express
believ
activ
signal
pathway
play
crucial
role
prevent
cell
tissu
undergo
oxid
stress
ascorb
acid
key
compound
antioxid
system
cell
tissu
biolog
medicin
properti
vitc
critic
care
manag
document
accept
viral
bacteri
infect
result
product
excess
cytokin
antioxid
given
control
pandem
nonavail
pathogenspecif
vaccin
drug
strengthen
fact
larg
dose
iv
vitc
shown
success
clinic
result
viral
ard
influenza
report
known
woman
develop
viral
ard
rhinoviru
admit
icu
respons
routin
treatment
place
ecmo
day
high
dose
iv
mgkg
h
dose
one
everi
h
initi
ecmo
amazingli
lung
patient
show
excel
improv
day
high
dose
iv
vitc
infus
improv
character
xray
imag
continu
improv
discharg
hospit
without
requir
addit
oxygen
month
xray
lung
indic
complet
cure
sever
medic
problem
influenza
treat
high
dose
iv
vitc
success
young
patient
recommend
take
high
dose
iv
vitc
mg
vitc
ml
ringer
solut
infus
min
condit
patient
improv
notabl
next
day
continu
take
oral
vc
mg
twice
daili
protect
action
ascorb
acid
shown
high
dose
iv
vitc
use
treat
new
zealand
farmer
primal
panacea
vitc
abl
cut
icu
stay
analysi
clinic
studi
icu
patient
found
mgday
iv
vitc
shorten
icu
stay
use
iv
vitc
sepsi
icu
case
report
major
reduct
death
possibl
dietari
antioxid
vitc
sulforaphan
help
manag
oxidativestressinduc
acut
inflammatori
lung
injuri
requir
mechan
ventil
anoth
antioxid
natur
curcumin
also
effect
inflamm
caus
pneumonia
nation
institut
health
nih
state
high
dose
iv
vitc
gkd
bodi
weight
safe
good
health
without
side
effect
past
centuri
opinion
vitc
use
treat
cancer
viral
infect
shown
promis
controversi
case
high
dose
vitc
shown
benefit
case
benefit
howev
new
knowledg
regard
pharmacokinet
properti
vitc
recent
preclin
studi
reviv
interest
util
highdos
vitc
cancer
treatment
similar
case
use
iv
vitc
antivir
especi
recent
believ
iv
vitc
particularli
effect
inhibit
product
cytokin
storm
due
pneumonia
extrem
rapidli
develop
diseas
high
mortal
rate
main
pathogenesi
acut
lung
injuri
caus
ard
death
antioxid
role
manag
condit
appropri
clinic
studi
report
demonstr
time
administr
high
dose
iv
vitc
improv
outcom
infect
addit
studi
detail
use
iv
vitc
treatment
sever
infect
pneumonia
definit
warrant
may
continu
happen
futur
sinc
develop
clinic
activ
vaccin
antivir
drug
target
specif
diseas
may
take
long
time
develop
use
iv
vitc
univers
agent
ard
may
benefit
behind
addit
clinic
studi
iv
vitc
oral
vc
liposomalencapsul
vc
target
situat
differ
mechan
requir
develop
soon
possibl
ab
wrote
first
draft
manuscript
bkb
first
revis
manuscript
author
improv
manuscript
author
receiv
fund
conflict
interest
declar
